NHS organisations should take into account the reasons why the company did not make an evidence submission when considering whether or not to recommend local use of idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment. If, after doing this, organisations still wish to consider idelalisib for treating follicular lymphoma that is refractory to 2 prior lines of treatment, they should follow the advice set out in the NHS Constitution for England and the National Health Service Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outline the approach that should be adopted when NICE guidance is unavailable.
NICE will review the position at any point if the company indicates that it wishes to make a full submission.
© National Institute for Health and Care Excellence 2014. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not-for-profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.